IL2 and renal cell carcinoma: The current analysis provided first information about quality of life experienced by metastatic RCC patients before treatment and 3 weeks after treatment initiation with s.c. IL-2, s.c. IFN-α2a, and p.o. 13-cis-retinoic acid as home therapy.